Previous Article | Next Article 
Journal of Virology, August 2007, p. 7852-7859, Vol. 81, No. 15
0022-538X/07/$08.00+0 doi:10.1128/JVI.02203-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Selection of Mutations in the Connection and RNase H Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Increase Resistance to 3'-Azido-3'-Dideoxythymidine
Jessica H. Brehm,1
Dianna Koontz,1
Jeffrey D. Meteer,1
Vinay Pathak,2
Nicolas Sluis-Cremer,1 and
John W. Mellors1*
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261,1
National Cancer Institute, Frederick, Maryland 217022
Received 6 October 2006/
Accepted 5 May 2007
Recent work indicates that mutations in the C-terminal domains of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) increase 3'-azido-3'-dideoxythymidine (AZT) resistance. Because it is not known whether AZT selects for mutations outside of the polymerase domain of RT, we carried out in vitro experiments in which HIV-1LAI or AZT-resistant HIV-1LAI (M41L/L210W/T215Y) was passaged in MT-2 cells in increasing concentrations of AZT. The first resistance mutations to appear in HIV-1LAI were two polymerase domain thymidine analog mutations (TAMs), D67N and K70R, and two novel mutations, A371V in the connection domain and Q509L in the RNase H domain, that together conferred up to 90-fold AZT resistance. Thereafter, the T215I mutation appeared but was later replaced by T215F, resulting in a large increase in AZT resistance (
16,000-fold). Mutations in the connection and RNase H domains were not selected starting with AZT-resistant virus (M41L/L210W/T215Y). The roles of A371V and Q509L in AZT resistance were confirmed by site-directed mutagenesis: A371V and Q509L together increased AZT resistance
10- to 50-fold in combination with TAMs (M41L/L210W/T215Y or D67N/K70R/T215F) but had a minimal effect without TAMs (1.7-fold). A371V and Q509L also increased cross-resistance with TAMs to lamivudine and abacavir, but not stavudine or didanosine. These results provide the first evidence that mutations in the connection and RNase H domains of RT can be selected in vitro by AZT and confer greater AZT resistance and cross-resistance to nucleoside RT inhibitors in combination with TAMs in the polymerase domain.
* Corresponding author. Mailing address: University of Pittsburgh School of Medicine, S818 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261. Phone: (412) 624-8512. Fax: (412) 383-7982. E-mail:
mellors{at}dom.pitt.edu
Published ahead of print on 16 May 2007.
Journal of Virology, August 2007, p. 7852-7859, Vol. 81, No. 15
0022-538X/07/$08.00+0 doi:10.1128/JVI.02203-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Sluis-Cremer, N., Koontz, D., Bassit, L., Hernandez-Santiago, B. I., Detorio, M., Rapp, K. L., Amblard, F., Bondada, L., Grier, J., Coats, S. J., Schinazi, R. F., Mellors, J. W.
(2009). Anti-Human Immunodeficiency Virus Activity, Cross-Resistance, Cytotoxicity, and Intracellular Pharmacology of the 3'-Azido-2',3'-Dideoxypurine Nucleosides. Antimicrob. Agents Chemother.
53: 3715-3719
[Abstract]
[Full Text]
-
Delviks-Frankenberry, K. A., Nikolenko, G. N., Maldarelli, F., Hase, S., Takebe, Y., Pathak, V. K.
(2009). Subtype-Specific Differences in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Connection Subdomain of CRF01_AE Are Associated with Higher Levels of Resistance to 3'-Azido-3'-Deoxythymidine. J. Virol.
83: 8502-8513
[Abstract]
[Full Text]
-
Garriga, C., Perez-Elias, M. J., Delgado, R., Ruiz, L., Perez-Alvarez, L., Pumarola, T., Lopez-Lirola, A., Gonzalez-Garcia, J., Menendez-Arias, L., on behalf of the Spanish Group for the Study of An,
(2009). HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations. J Antimicrob Chemother
64: 251-258
[Abstract]
[Full Text]
-
Ehteshami, M., Beilhartz, G. L., Scarth, B. J., Tchesnokov, E. P., McCormick, S., Wynhoven, B., Harrigan, P. R., Gotte, M.
(2008). Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3'-Azido-3'-deoxythymidine through Both RNase H-dependent and -independent Mechanisms. J. Biol. Chem.
283: 22222-22232
[Abstract]
[Full Text]
-
Delviks-Frankenberry, K. A., Nikolenko, G. N., Boyer, P. L., Hughes, S. H., Coffin, J. M., Jere, A., Pathak, V. K.
(2008). HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc. Natl. Acad. Sci. USA
105: 10943-10948
[Abstract]
[Full Text]
-
Hachiya, A., Kodama, E. N., Sarafianos, S. G., Schuckmann, M. M., Sakagami, Y., Matsuoka, M., Takiguchi, M., Gatanaga, H., Oka, S.
(2008). Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors. J. Virol.
82: 3261-3270
[Abstract]
[Full Text]
-
Kajiwara, K., Kodama, E., Sakagami, Y., Naito, T., Matsuoka, M.
(2008). Dual-Reporter Phenotypic Assay for Human Immunodeficiency Viruses. J. Clin. Microbiol.
46: 792-795
[Abstract]
[Full Text]